Visualization of Gallbladder with In-111 Octreotide Scan
İn-111 Octreotid Sintigrafisinde Safra Kesesinin Görüntülenmesi

Filiz Özülker, Tamer Özülker, M. Tank Tatoğlu, Aysun Küçüköz Uzun
Okmeydanı Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey

Abstract
A 54-year-old woman underwent octreotide scintigraphy for evaluation of neuroendocrine tumor recurrence. The images demonstrated unusual uptake in gallbladder area in addition to physiologic uptake at other tissues. Whole-body planar and SPECT imaging were repeated after fatty meal ingestion at 28 hours in order to figure out whether this activity was physiologic or not. Since the unusual uptake in the gallbladder was still detected at these images, additional images were obtained 72 hours after radionuclide injection. The activity in the gallbladder disappeared at these images revealing the physiologic nature of this unusual accumulation.

Key Words: In-111-Octreotide, gallbladder, neuroendocrine tumors

Conflicts of Interest: The authors reported no conflict of interest related to this article.

Özet
Elli dört yaşında bayan hastaya, nöroendokrin tümörün olası rekürrensünün saptanması amacıyla oktreotid sintigrafisi uygulandı. Görüntülerde, diğer dokulardaki fiziolojik tutulumlara ek olarak safra kesesi bölgesinde olağandışı tutulum görüldü. Safra kesesiindeki tutulumun fiziolojik olup olmadığını anlamak için 28. saatte yağlı yemek yenmesi sonrası tüm-vücut planar ve SPECT görüntüleri tekrarlandı. Safra kesesi bölgesindeki olağandışı aktivitenin bu görüntülerde de devam etmesi üzerine radionüklidin enjeksiyonundan sonra 72. saatte görüntüler tekrarlandı. Bu görüntülerde safra kesesindeki aktivitenin kaybolması bu olağandışı tutulumun fiziolojik karakterde olduğunu gösterdi.

Anahtar Kelimeler: In-111-Oktreotid, safra kesesi, nöroendokrin tümörler

Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çatışma bildirmemiştir.

Introduction
In-111 octreotide scan is widely used in the evaluation of neuroendocrine tumors and physiologic accumulation of the activity might lead to misinterpretation (1). Herein, we present a patient with neuroendocrine tumor who was imaged with In-111 octreotide and showed unusual uptake in the gallbladder.

Case Report
A 54-year-old woman was referred to our department of nuclear medicine for In-111 octreotide (Octreo Scan, Mallinckrodt Medical, Petten, the Netherlands) scanning. The patient had undergone an operation for neuroendocrine carcinoma 8 months ago and octreotide scintigraphy was planned with the purpose of detection of any possible recurrences.
Octreotide scintigraphy was performed and whole-body planar and SPECT were acquired at 4 and 24 hours after administration of 5 mCi (185 MBq) In-111 octreotide. The images demonstrated physiologic uptake at the liver, spleen, kidneys and bladder along with an unusual uptake at the location of gallbladder. Whole-body planar and SPECT imaging were repeated after fatty meal ingestion at 28 hours in order to differentiate pathological activity and physiologic uptake in the gallbladder. The unusual uptake in the gallbladder was still detected at these images; therefore additional images were obtained 72 hours after radionuclide injection. The activity in the gallbladder disappeared at these images indicating the physiologic nature of this unusual accumulation (Figure 1 and Figure 2).

**Literature Review and Discussion**

In-111 octreotide has been widely used for 20 years for scintigraphic localization of primary and metastatic neuroendocrine tumors that express somatostatin receptors. Normal physiologic distribution of In-111 octreotide includes faint visualization of thyroid, pituitary gland and marked increased uptake in the liver, spleen, kidneys and bladder. Although rarely encountered, false-positive studies have been reported due to increased activity at nonmalignant pathologies such as Paget’s disease, parathyroid adenoma, cholecystitis, thrombus, abscess, infection, pulmonary fibrosis, pleural plaques and uterine myomas (2,3,4,5,6,7,8,9). Only a few cases in the literature have reported increased In-111 octreotide activity in the gallbladder (10,11,12,13,14). The unusual accumulation of In-111 octreotide in benign pathologies may be explained partially by the presence of somatostatin receptors in activated leukocytes during chronic inflammatory processes (15,16). After injection, In-111 octreotide is rapidly cleared by the kidneys (85% of the injected dose is recovered in the urine by 24 hours) and approximately 2% of the injected dose undergoes hepatobiliary excretion. Functional impairment is another possible reason for gallbladder visualization due to a delay in radionuclide excretion. Turner et al. showed that gallbladder motility is impaired in patients receiving long-acting somatostatin analogue and there might be an association with octreotide treatment and gallstone development (17). In our case a gallbladder inflammation that could explain such an uptake was not identified. Krausz et al. encountered unusual uptake in the gallbladder in 3 patients who underwent In-111 octreotide scintigraphy, and this activity disappeared after a fatty meal. It is also advised to administer a laxative on the day before injection, especially when the abdomen is the area of interest (18). Kurtaran et al. proposed that this problem might be prevented by performing a dual tracer SPECT imaging using In-111 octreotide and hepatobiliary agent, 99mTc-trimethyl-brom-imino-diaceitic acid (TBIDA) with dual energy window sets (13). In our case the activity in the gallbladder persisted even after the patient had a fatty meal, but it disappeared in late images at 72 hours after injection.

We concluded that the images in In-111 octreotide scintigraphy should not be obtained in the fasting state and if significant uptake is seen in the gallbladder area, late images up to 72 hours should be acquired.

**Concept:** Filiz Özülker  
**Design:** Filiz Özülker, Tamer Özülker, Tank Tatoğlu  
**Data Collection or Processing:** Filiz Özülker, Tamer Özülker  
**Analysis or Interpretation:** Filiz Özülker  
**Literature Search:** Aysun Küçükoğuz Uzun, Filiz Özülker, Tank Tatoğlu  
**Writing:** Filiz Özülker  
**Financial Disclosure:** None  
**Peer-review:** Externally peer-reviewed.
References

1. Biersack HJ, Briele B, Hotze AL, Oehr P, Qian L, Mekkawy MA, Shih WJ. The role of nuclear medicine in oncology. Ann Nucl Med 1992;6:131-136.

2. Kang S, Mishkin FS. Visualization of Paget’s disease during somatostatin receptor scintigraphy. Clin Nucl Med 1999;24:900-902.

3. Servaes S, El-Haddad G, Zhuang H. Intense octreotide activity in a thrombus. Clin Nucl Med 2008;33:140-141.

4. Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, Marchal J, Raguin O, Gruaz-Guyon A, Reubi JC, Le Guludec D, Crestani B. Increased uptake of 111 In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006;47:1281-1287.

5. Lonneux M, Jamar F, Leners N, Pieters T, Pauwels S. Uptake of In-111 pentetreotide by pleural plaques. Clin Nucl Med 1998;23:298-301.

6. Stoffel M, Jamar F, Donckier J, Hainaut P, Decoster P, Beekers C, Pauwels S. Increased uptake of indium-111 pentetreotide up to 10 years after external thoracic irradiation: report of two cases. Eur J Nucl Med 1996;23:723-726.

7. Valero M, Boan JF, Rodriguez-Spiteri N, Torre W, Richter JA. False positive In-111 DTPA octreotide scintigraphy resulting from lung abscess in a patient with metastatic neuroendocrine pancreatic neoplasm. Clin Nucl Med 2006;31:20-22.

8. Yenson T, Khalil T, Larcos G. Pneumonia can cause 111 Indium octreotide uptake. Aust Radiol 2006;50:218-221.

9. Luisa M. Mena, Francisco Martin, Ignacio Jiménez. In-111 Pentetreotide Uptake in a Uterine Myoma. Clin Nucl Med 2010;35:524-525.

10. Niederkohr RD, McDougall IR. Incidental gallbladder visualization on nonhepatobiliary nuclear medicine studies: case series and review of the literature. Clin Nucl Med 2007;32:915-919.

11. Gedik GK, Kiratli PQ, Erbas B. Visualization of gallbladder with In-111 labeled octreotide in post prandial state 2006;20:557-560.

12. Krausz Y, Shibley N, De Jong RB. Gallbladder visualization with In-111 labeled octreotide 1994;19:133-135.

13. Kurtaran A, Ofluoglu S, Traub T, Tribl B, Speiser P, Grabenwöger F, Schima W, Dudczak R, Virgolini I. An Unusual Visualization of the Gallbladder by Somatostatin Receptor (SSTR) Scintigraphy: Usefulness of Hepatobiliary Imaging for Differential Diagnosis. Am J Gastroenterol 2000;95:1367-1368.

14. Karaçavuş S, Kula M, Cihan KZ, Unlühızarcı K, Tutuş A, Bayram F, Coban G. Octreotide uptake in parathyroid adenoma. Mol Imaging Radionud Ther 2012;21:77-79.

15. Weinstock JV, Elliott DE. The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur J Endocrinol 2000;143:15-19.

16. Elliott DE, Li J, Blum AM, Metwalli A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999;29:2454-2463.

17. Turner HE, Lindsell DR, Vardavale A, Thillainayagam AV, Wass JA. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol 1999;141:590-594.

18. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42:1134-1138.